Patent settlements will prop up US sales of Sanofi-Aventis's Eloxatin
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has stated that it has settled patent infringement suits in two US courts with six generic manufacturers over its anticancer Eloxatin (oxaliplatin injection). In return for agreeing to take their generic versions off the US market from late June 2010 until August 2012, the companies will be authorised to sell generic oxaliplatin under a licence months before the Eloxatin patents at issue expire.